MedTrace Logo

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2026-05-14

No results posted yet for this study

Summary

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Conditions

Interventions

DRUG

64Cu-SAR-bisPSMA

All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

Sponsors & Collaborators

  • Clarity Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Clarity Pharmaceuticals · Clarity Pharmaceuticals

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-21
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06056830 on ClinicalTrials.gov